NINLARO

July 18, 2018

Ninlaro Maintenance Therapy Fares Well in Phase 3 Multiple Myeloma Trial

News

Takeda‘s proteasome inhibitor Ninlaro (ixazomib) prevents multiple myeloma from progressing or returning when given as a maintenance therapy to patients who responded to first-line therapy and stem cell transplant, a Phase ... Read more

July 9, 2018July 9, 2018

Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows

News

Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple myeloma, although it’s likely more toxic than once-weekly Ninlaro, according to ... Read more

March 28, 2018

ACCoRd Trial to Test Ninlaro Treatment for ASCT-Relapsed Multiple Myeloma

News

A new Phase 3 clinical trial called ACCoRd is underway to investigate the benefits of adding Ninlaro (ixazomib) – a proteasome inhibitor – to the conditioning regimen prior to ... Read more

February 9, 2018February 9, 2018

Multiple Myeloma Patients in UK Gain Access to Ninlaro through Cancer Drugs Fund

News

Multiple myeloma patients in the United Kingdom can now potentially benefit from a new oral pill sold as Ninlaro (ixazomib) after Takeda, the maker of the medicine, struck a ... Read more

January 12, 2018January 12, 2018

Multiple Myeloma Patients Remain On Treatment Far Less than in Clinical Trials, Study Finds

News

Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter than those participating in clinical trials, a study found. ... Read more

June 28, 2017June 28, 2017

Potential Use of Ninlaro as Maintenance Therapy in Multiple Myeloma Shown in Phase 1/2 Trials

News

Patients with newly diagnosed multiple myeloma benefit significantly from a combination of Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone, followed by Ninlaro maintenance therapy, according to long-term follow-up data ... Read more

June 23, 2016June 23, 2016

Relapsed/Refractory Multiple Myeloma Drug by Takeda Receives Negative Opinion from EMA

News

Takeda Pharmaceutical Company Limited has recently received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), which recommended against authorizing NINLARO (ixazomib) capsules for ... Read more

May 11, 2016May 11, 2016

Phase 3 Study of Ixazomib in Select Multiple Myeloma Patients Reports Benefits

News

Takeda Pharmaceutical Co. has announced that Ninlaro (ixazomib), combined with lenalidomide and dexamethasone as a therapeutic approach for relapsed and/or refractory multiple myeloma (MM), markedly increases a patient’s progression free ... Read more

April 29, 2016April 29, 2016

Takeda Publishes Promising Trial Results on Ixazomib, an Approved Drug to Treat Relapsed Multiple Myeloma

News

Takeda Pharmaceutical has published promising data from the TOURMALINE-MM1 Phase 3 clinical trial of patients with relapsed and/or refractory multiple myeloma (MM), treated with the combination of once-weekly oral Ninlaro (ixazomib) capsules ... Read more